HomeNovartis

  • Increased Anxiety & Depression in Higher frequency Migraine patients, new research study says

    • August 20, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Novartis wins Aimovig approval for launch in the EU markets

    • August 3, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Unprecedented demand for Aimovig reflects strong unmet need in Migraine, says Novartis CEO

    • July 20, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Aimovig for Migraine receives positive CHMP opinion by EMA, might get approved soon in EU

    • June 2, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Ofatumumab shows efficacy in RRMS, highlight trial results

    • May 25, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • FDA approves Aimovig, first aCGRP drug for preventive treatment of Migraine

    • May 18, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Gilenya approved by FDA for Pediatric RMS patients

    • May 14, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more